Pharma/fine chemicals roundup—6 December
11:34 AM MST | December 6, 2012 | By DEEPTI RAMESH
Cambrex appoints former Teva CEO as board vice chairman
Cambrex (East Rutherford, NJ) says it has appointed Shlomo Yanai to its board of directors and will serve as its nonexecutive vice chairman. Yanai had been the president and CEO of Teva Pharmaceutical (Petaḥ Tiqwa, Israel)—the largest generic pharmaceutical manufacturer in the world—until his retirement in mid-2012. As vice chairman of the Cambrex board, he will work closely with the company's other directors and its leadership team to formulate and help execute Cambrex's growth strategies, the company says.
Report: API industry in Asia to grow
The active pharmaceutical ingredient industry in the Asia/Pacific region earned revenues of $1.12 billion in 2011 and is estimated to reach $1.79 billion in 2018, according to recent analysis by Frost & Sullivan. The growth will largely be due to the growing population and increasing incidence of life style–diseases, Frost & Sullivan says.
Lonza to sell Arch performance urethanes and organics business to Monument Chemical
Lonza says it has signed a definitive agreement with Monument Chemical (Indianapolis) for the sale of substantially all of the assets of Lonza’s performance urethanes and organics business in the United States, located at Brandenburg, KY. The assets became a part of Lonza through the acquisition of Arch Chemicals (Norwalk, CT) in 2011. Lonza said last month that it is in discussions for the possible sale of the performance urethanes and organics business. The sale will be completed by the end of 2012, Lonza says. Financial terms of the deal were not disclosed.
Bayer supports pharmaceutical research project
Bayer says that its Bayer HealthCare subsidiary and Leiden University (Leiden, Netherlands) will coordinate a newly founded international consortium, called Kinetics for Drug Discovery (K4DD), which has been launched to explore a novel concept in drug discovery and to tackle a problem in the development of new drugs. Although successful in early phases of development, many drug candidates fail in clinical studies because of lack of efficacy, Bayer says. The new five-year project will focus on optimizing binding kinetics for drug candidates with the goal of improving drug design. The consortium is financially supported with €20 million ($26 million) by the Innovative Medicines Initiative (Brussels). The K4DD consortium consists of pharma companies, universities, knowledge institutes, and smaller companies from Europe.
Hovione and Solvias collaborate to improve drug solubility
Active pharmaceutical ingredients producer Hovione (Loures, Portugal) says it has established a collaboration with Solvias (Basel, Switzerland) focused on the development and good manufacturing practice supply of pharmaceutical cocrystals. This move strengthens Hovione’s expertise in overcoming drug delivery challenges and also the supply of GMP materials from phase I to commercial scale, with Solvias’s capabilities in solid-state chemistry.
Connect with IHS Chemical Week
Our related sites